Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

344P - Clinical outcomes of platinum-based polichemotherapy in patients with advanced breast cancer: A 10-year single institutional experience

Date

17 Sep 2020

Session

E-Poster Display

Topics

Cytotoxic Therapy

Tumour Site

Breast Cancer

Presenters

Maria Alice Franzoi

Citation

Annals of Oncology (2020) 31 (suppl_4): S348-S395. 10.1016/annonc/annonc268

Authors

M.A. Franzoi1, R.S. Conde2, S.C. Ferreira2, D. Eiger1, A.H. Awada3, E. de Azambuja1

Author affiliations

  • 1 Clinical Trial Support Unit, Institute Jules Bordet, 1000 - Brussels/BE
  • 2 Medical Oncology Department, Instituto Portuguès de Oncologia de Lisboa Francisco Gentil E.P.E. (IPO Lisboa), 1099-023 - Lisbon/PT
  • 3 Department Of Oncology Medicine, Institute Jules Bordet, 1000 - Brussels/BE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 344P

Background

Although the prognosis of metastatic breast cancer (MBC) has improved, several patients (pts) still develop sooner or later high burden metastases (mets) with function alterations or visceral crisis (VC). For these pts, polichemotherapy is commonly used and recommended by clinical guidelines in VC. Data reporting the real effectiveness of this strategy are scanty. Outcomes of MBC pts treated with platinum-based polichemotherapy (P-CT) at the Institut Jules Bordet (IJB) during a period of 10 years were reviewed.

Methods

Retrospective review of medical charts of pts with MBC receiving P-CT in IJB between Jan 2008 and Dec 2018. VC was defined according to ABC 4 criteria. Overall survival (OS) was estimated by Kaplan-Meier and comparisons by log-rank test. Cox proportional hazards models was used for multivariate analysis.

Results

441 pts were identified: 370 (84%) with disease recurrence and 71 (16%) with de-novo MBC. As for MBC subtype, 180 (41%) had ER-positive (ER+)/HER2-negative (HER2-), 116 (26%) ER+/HER2+, 34 (8%) ER-/HER2+, and 111 (25%) triple negative BC. Visceral mets were observed in 430 (97.5%) pts and 261 (59%) presented VC. VC involved mainly liver dysfunction (n=134), lung lymphangitis (n=45), symptomatic brain mets (n=28), peritoneal carcinomatosis with bowel obstruction (n=25) and leptomeningeal mets (n=22). Median OS with P-CT in the entire cohort was 6.1 months, without differences by MBC subtype (p=0.076). Pts with VC had statistically lower OS than pts without VC (3.7 vs. 8.6 months; p<0.001). On multivariate analysis, the variables statistically correlated with worse OS were: hyperbilirubinemia (HR 1.92; 95% CI 1.33-2.77; p<0.001), ECOG ≥2 (HR 1.66; 95% CI 1.03-2.65; p=0.035) and ECOG ≥3 (HR 2.43; 95% CI 1.35-4.05, p=0.002), >3 previous treatment lines (HR 2.25; 95% CI 1.53-3.32, p<0.001). Of the 261 pts with VC, 106 (40.5%) presented a resolution of VC which was correlated with better OS (9.3 vs. 2.0 months, HR 0.25; 95% CI 0.19-0.34; p<0.001).

Conclusions

Pts who overcome VC benefit from P-CT with OS similar to pts without VC. Hyperbilirubinemia, poor ECOG and >3 previous treatment lines are significant prognosis factors and could be markers of futility for this treatment in MBC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Institut Jules Bordet.

Funding

Has not received any funding.

Disclosure

D. Eiger: Research grant/Funding (self), Funding for his fellowship (2018-2019): Novartis. A.H. Awada: Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Lilly; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Amgen; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Eisai; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): BMS; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Pfizer; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): MSD; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Genomic Health; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Ipsen; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Bayer; Advisory/Consultancy, Speaker Bureau/Expert testimony: Leo Pharma. E. de Azambuja: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche/ GNE; Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self), Advisory/Consultancy: Seattle Genetics; Travel/Accommodation/Expenses: GSK/Novartis; Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Servier. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.